Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients
Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients
corcept醫療宣佈在ADA第84屆科學會議上公佈CATALYST臨床試驗的結果。該研究表明難以控制的2型糖尿病患者中高皮質酮綜合徵的患病率爲24%。這是迄今爲止最大的研究，共有1,055名患者參與。
- Results from the CATALYST clinical trial were presented at the American Diabetes Association's 84th Scientific Sessions at a featured plenary session titled: "Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes"
- With 1,055 patients enrolled, CATALYST is the largest and most rigorous study ever conducted to assess the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes
- Results demonstrate a hypercortisolism prevalence rate of 24 percent in this patient population
- CATALYST臨床試驗的結果在美國糖尿病協會第84次科學會議的特色板塊"難以控制的2型糖尿病患者的高皮質醇血癥患病率"上進行了展示。
- CATALYST是迄今爲止最大、最嚴謹的研究，共招募了1055名患有難以控制的2型糖尿病患者。
- 結果表明，該患者人群中高皮質醇血癥的患病率爲24%。